Calcitonin release from medullary thyroid carcinoma by thyrotropin-releasing hormone: comparison with calcium injection

1992 ◽  
Vol 126 (4) ◽  
pp. 325-328 ◽  
Author(s):  
Seiichi Oishi ◽  
Jouji Yamauchi ◽  
Yasuko Fujimoto ◽  
Shinichiro Hamasaki ◽  
Teruhisa Umeda ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Normal Subjects ◽  
Thyrotropin Releasing Hormone ◽  
Medullary Thyroid ◽  
Releasing Hormone ◽  
Significant Difference ◽  
Calcium Infusion ◽  
Calcium Injection ◽  
Peak Value

The effects of thyrotropin-releasing hormone on the release of calcitonin were investigated in 15 normal subjects and 12 patients with medullary thyroid carcinoma. The present study also compared the effect of TRH stimulation with calcium infusion test on calcitonin release in patients with medullary thyroid carcinoma. In normal subjects, calcitonin increased from a basal value of 7.5±2.5 pmol/l to a peak value of 9.4±3.0 pmol/l (p<0.01) after iv injection of synthetic TRH (500 μg). Basal calcitonin values in patients with medullary thyroid carcinoma were high (1216±2230 pmol/l, p<0.05), and TRH induced a further increase in calcitonin to 1 842±3149 pmol/l in all the patients (p< 0.05). They had a peak value of 7891±13 528 pmol/l after the calcium infusion, which was significantly higher than the basal value of 1463±2630 pmol/l (p<0.05). All medullary thyroid carcinoma patients displayed a marked calcitonin increase after TRH and calcium stimulation. Although the increase in serum calcitonin after TRH injection was lower than that after calcium injection (1.6-fold vs 5.4-fold, p <0.05), there was no significant difference in mean peak calcitonin value following TRH and calcium injection in patients with medullary thyroid carcinoma. These results indicated that TRH could stimulate calcitonin release from the thyroid C-cells in both normal subjects and patients with medullary thyroid carcinoma.

A Short Calcium Infusion in the Diagnosis of Medullary Thyroid Carcinoma

1974 ◽  
Vol 39 (1) ◽  
pp. 108-111 ◽  
Author(s):  
J. G. PARTHEMORE ◽  
D. BRONZERT ◽  
G. ROBERTS ◽  
L. J. DEFTOS
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Calcium Infusion

scholarly journals Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study

2013 ◽  
Vol 168 (5) ◽  
pp. 779-786 ◽  
Author(s):  
J A A Meijer ◽  
L E H Bakker ◽  
G D Valk ◽  
W W de Herder ◽  
J H W de Wilt ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Multicenter Study ◽  
Radioactive Iodine ◽  
Disease Free Survival ◽  
Distant Metastases ◽  
Medullary Thyroid ◽  
Clinical Appearance ◽  
Significant Difference

ObjectiveRadioactive iodine (RAI) therapy in medullary thyroid carcinoma (MTC) is applied in some centers, based on the assumption that cross-irradiation from thyroid follicular cells may be beneficial. However, no systematic studies on the effect of RAI treatment in MTC have been performed. The aim of this study was to analyze the effect of RAI treatment on survival in MTC patients.DesignRetrospective multicenter study in eight University Medical Centers in The Netherlands.MethodsTwo hundred and ninety three MTC patients without distant metastases who had undergone a total thyroidectomy were included between 1980 and 2007. Patients were stratified by clinical appearance, hereditary stage, screening status, and localization. All patients underwent regular surgical treatment with additional RAI treatment in 61 patients. Main outcome measures were disease-free survival (DFS) and disease-specific survival (DSS). Cure was defined as biochemical and radiological absence of disease.ResultsIn multivariate analysis, stratification according to clinical appearance (P=0.72), hereditary stage (P=0.96), localization (P=0.69), and screening status (P=0.31) revealed no significant effects of RAI treatment on DFS. Multivariate analysis showed no significant difference in DSS for the two groups stratified according to clinical appearance (P=0.14). Owing to limited number of events, multivariate analysis was not possible for DSS in the other groups of stratification.ConclusionsBased on the results of the present analysis, we conclude that RAI has no place in the treatment of MTC.

Elevated serum calcitonin levels in patients with thyroid disorders

1984 ◽  
Vol 107 (4) ◽  
pp. 476-481 ◽  
Author(s):  
Seiichi Oishi ◽  
Tatsuya Shimada ◽  
Junichi Tajiri ◽  
Junnosuke Inoue ◽  
Tatsuo Sato
Keyword(s):  
Thyroid Carcinoma ◽  
Elevated Serum ◽  
Normal Subjects ◽  
Thyroid Disorders ◽  
Infusion Test ◽  
Serum Calcitonin ◽  
Medullary Thyroid ◽  
Before And After ◽  
Calcium Infusion ◽  
Calcium Load

Abstract. Serum calcitonin was measured by radioimmunoassay (RIA) in 63 patients with hyperthyroidism, 37 with hypothyroidism, 9 with surgically proven medullary thyroid carcinoma (MTC) and 81 normal subjects. Provocative tests of calcitonin by calcium infusion were performed in 11 with hyperthyroidism, 10 with hypothyroidism, 6 with MTC and 14 normal subjects. Changes of calcitonin were also studied before and after treatment in 17 patients with hyperthyroidism and 12 with hypothyroidism. The basal calcitonin levels were increased in both hyperthyroidism (117 ± 60.1 pg/ml (mean ± sd): n = 63, P < 0.001) and hypothyroidism (137 ± 107 pg/ml, n = 37, P < 0.001), and significantly increased in MTC 14765 ± 25039 pg/ml, range 390 to 70400 pg/ml, n = 9, P < 0.001) compared with those in normal subjects (45.8 ± 22.3 pg/ml, n = 81). Increases of calcitonin during calcium load (iv 4.5 mg calcium/kg for 10 min) were significantly lower in both hyperthyroidism and hypothyroidism patients than in those in MTC. The calcitonin levels were not correlated with the serum T3, T4, TSH concentrations or titres of serum antithyroid antibodies in hyperthyroidism and hypothyroidism. We found some tendency toward decreasing calcitonin levels with the euthyroid state after treatment in both groups, but the changes were not significant. Although exact mechanisms of increased calcitonin in hyperthyroidism and hypothyroidism were not clear, our findings suggest that a 2- to 3-fold elevation of calcitonin levels in these patients did not indicate malignancy; MTC could be readily differentiated by a calcium infusion test.

scholarly journals Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case

2021 ◽  
Vol 11 ◽  
Author(s):  
Tian Yang ◽  
Longsheng Huang ◽  
Chang Chen ◽  
Han Luo ◽  
Yong Jiang
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Nodular Goiter ◽  
Sporadic Case ◽  
Clinicopathological Characteristics ◽  
Braf V600e ◽  
Biological Behavior ◽  
Promoter Mutation ◽  
Medullary Thyroid ◽  
Significant Difference

BackgroundIt has been debated whether familial non-medullary thyroid carcinoma (FNMTC) is more aggressive and has a worse prognosis than sporadic non-medullary thyroid carcinoma (SNMTC). Our aim was to compare the invasiveness and prognosis of FNMTC and SNMTC by their biological behavior and molecular changes.Method and MaterialOur group mainly compared 106 patients with FNMTC whom have complete clinicopathological data during 2011–2019 in West China Hospital, Sichuan University, and 212 randomly selected cases with SNMTC were included to compare their biological behavior, recurrence and mortality, and molecular expression of BRAF V600E and TERT promoter. At the same time, FNMTC cases were divided into four subgroups, namely, two affected members group, three or more affected members, parent/offspring group, and sibling group, and they were compared with SNMTC separately to analyze the difference in their invasiveness and prognosis.ResultsWe found that the mean tumor size of FNMTC (0.96 ± 0.53cm) was smaller than that of SNMTC (1.15 ± 0.72 cm) (p = 0.020), while no significant difference in the incidence of other clinicopathological factors, including bilateral growth, capsular invasion, with thyroid nodular goiter or not, multifocality, lymph node metastasis, extrathyroidal extension, iodine 131 treatments, T stage, and American Joint Committee on Cancer (AJCC) stage, was observed between FNMTC and SNMTC (p &gt; 0.05), between each FNMTC subgroup (p &gt; 0.05), and between each FNMTC subgroup and SNMTC (p &gt; 0.05). There was no significant difference in recurrence, mortality, and BRAF V600E and TERT promoter mutation between FNMTC and SNMTC, among which 50/60 (83.33%) of FNMTC patients had BRAF V600E mutation and 1/32 (3.13%) had TERT promoter mutation, while the mutation rates of SNMTC were 93/108 (86.11%) and 3/64 (4.69%) (p &gt; 0.05).ConclusionThere was no significant difference in invasiveness and prognosis between FNMTC and SNMTC by biological behavior, patient survival, and molecular level comparison.

Sign in / Sign up

Export Citation Format

Share Document